Penciclovir and Famciclovir

Chemical nature and spectrum of action

Penciclovir belongs to a group of antiviral agents that are acyclic guanine analogues in their chemical structure. Compared to the reference drug of this group, acyclovir, the main structural difference lies in the presence of the 3'-hydroxyl group located in the side chain of the molecule. This seemingly minor detail radically changes the mechanism of the drug's interaction with viral DNA.

Despite its structural features, the spectrum of antiviral action of penciclovir is completely analogous to that of acyclovir. The drug exhibits high clinical activity against herpes simplex viruses (HSV), which cause skin and mucous membrane lesions, as well as the Varicella zoster virus (VZV), which is the causative agent of chickenpox and shingles.

Mechanism of action at the cellular level

The mechanism of action of penciclovir is realized strictly inside infected cells and includes several consecutive stages that share similarities as well as important differences from other acyclic nucleosides:

1. Primary activation. As with acyclovir, the process is triggered by a specific viral enzyme—thymidine kinase. This enzyme performs the first phosphorylation of the molecule in the infected cell.
2. Intracellular pharmacokinetics. Subsequent phosphorylation steps lead to the formation of the active metabolite, penciclovir triphosphate. Its most important feature is that it accumulates in affected cells in very large amounts and persists there significantly longer (up to 20 hours) than acyclovir triphosphate.
3. Enzyme blockade. The active triphosphate affects viral DNA polymerase. The type of interaction is competitive inhibition. Interestingly, penciclovir inhibits this enzyme weaker than acyclovir; however, this disadvantage is fully compensated by the duration of the drug's stay inside the cell.

Effect on the DNA chain: key difference

The most important pharmacodynamic difference between the drugs lies in their effect on the assembly process of viral DNA.

Acyclovir, upon incorporation into the synthesized chain, causes its immediate termination because it lacks a point for attaching the next element.

Penciclovir acts differently: it does not cause termination of the DNA chain. This occurs precisely due to the presence of that same 3'-hydroxyl group in the side chain. This group is physically necessary for the attachment of subsequent nucleotides. Thus, chain synthesis can formally continue, but due to competitive inhibition of DNA polymerase, the formation of full-fledged viral particles is reliably blocked.

Pharmacokinetic issues and the creation of famciclovir

The main disadvantage of penciclovir is its extremely low oral bioavailability, which is only about 5%. Because of this, in its pure form, the drug is used exclusively topically (for example, in the form of a cream for recurrent herpes simplex). Upon topical application, systemic absorption and bioavailability remain low, making it safe but unsuitable for treating systemic infections.

To solve the problem of delivering the active substance into the systemic bloodstream, the famciclovir molecule was developed.

Famciclovir is a classic prodrug (chemically the diacetyl ester of 6-deoxypenciclovir). The rationale for its prescription is based on the following principles:

• Famciclovir itself has absolutely no antiviral activity.
• When taken orally, it is absorbed very well from the gastrointestinal tract.
• During intestinal absorption and immediately after it, the molecule undergoes intensive metabolism.
• As a result of chemical transformations, the active compound—penciclovir—is released into the systemic bloodstream, which then penetrates cells and begins its antiviral cycle.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• The role of viral thymidine kinase in the activation of acyclic nucleosides
• Competitive enzyme inhibition: pharmacodynamic features
• Metabolism of 6-deoxypenciclovir diacetyl ester in the intestinal wall
• Comparative characteristics of topical antiherpetic drug formulations

Other topics in the "Antivirals" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.